DEVELOP A HEMOCOMPATIBLE, EASY-TO-USE, COST-EFFECTIVE BLOOD PURIFIC

开发一种血液相容性、易于使用、经济高效的血液净化剂

• 批准号: 8740701
• 负责人: PHILLIP CHAN
• 金额: $ 20.34万
• 依托单位: CYTOSORBENTS, INC.
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-05 至 2014-03-04
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8740701
• 关键词: Adsorption; Antibodies; Blood; Catheters; Characteristics; Coronary; Coronary artery; Coronary sinus structure; Data; Devices; Hemoglobin; Lipids; Methods; Mitral Valve; Mitral Valve Insufficiency; Patient Selection; Patients; Phase; Polymers; Potassium; Proteins; Research; Research Personnel; Risk; System; United States National Institutes of Health; base; commercialization; cost effective; implantable device; improved; novel

Red blood cell (RBC) products for transfusion undergo metabolic and physical changes during storage characterized as RBC "storage lesions" that may result in extravascular hemolysis and inflammation, vasoconstriction, and potentially compromised oxygenation upon transfusion. To address this defect, we have proposed the rational design and development of HemoDefend, a hemocompatible, highly porous polymer bead optimized to broadly remove contaminants such as free hemoglobin, potassium, reactive antibodies, bioactive lipids, inflammatory cytokines, reactive proteins and microvesicles from stored pRBCs based on a proven pore capture and surface adsorption technology platform. These hemocompatible beads would be assessed in two configurations: 1) Beads-in-a-Bag, and 2) a dockable, in-line filter. In the first approach, the beads will be placed directly into the blood bag to adsorb blood contaminants during the storage period. In the second approach, the beads would be contained in a small in-line cartridge placed between the blood bag and the patient. After identifying optimal polymer sorbents, we will evaluate each test configuration for the ability to remove 11 contaminants and inflammatory mediators from pRBC units. Given the extended direct contact with erythrocytes, we will specifically evaluate seven parameters to assess hemocompatibility of the bead candidates. We will also evaluate whether HemoDefend treatment can prevent some of the deleterious morphological changes that occur to stored RBCs using image capture and differential cell counting. The outcome will be the demonstration of a powerful and easy-to-use blood purification technology to maintain and potentially improve the quality and safety of stored blood.

用于输血的红细胞（RBC）产品在储存期间发生代谢和物理变化，其特征为RBC“储存损伤”，可能导致血管外溶血和炎症、血管收缩和输血时潜在的氧合受损。为了解决这一缺陷，我们提出了HemoDefend的合理设计和开发，HemoDefend是一种血液相容性、高度多孔的聚合物珠粒，经过优化，可广泛清除污染物，如游离血红蛋白、钾、反应性抗体、生物活性脂质、炎性细胞因子、反应性蛋白和储存的pRBC中的微囊泡，基于经验证的孔捕获和表面吸附技术平台。这些血液相容性微珠将在两种配置中进行评估：1）袋中微珠，和2）可对接的在线过滤器。在第一种方法中，将微珠直接放入血袋中，以在储存期间吸附血液污染物。在第二种方法中，珠粒将被包含在放置在血袋和患者之间的小型在线盒中。在确定最佳聚合物吸附剂后，我们将评估每个测试配置从pRBC单元中去除11种污染物和炎症介质的能力。鉴于与红细胞的长期直接接触，我们将专门评价7个参数，以评估微珠候选物的血液相容性。我们还将使用图像采集和细胞分类计数来评估HemoDefend治疗是否可以预防储存RBC发生的一些有害形态学变化。其结果将是展示一种强大且易于使用的血液净化技术，以保持并可能提高储存血液的质量和安全性。